Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎

F. Palandri, G.A. Palumbo, A. Iurlo, N. Polverelli, G. Benevolo, M. Breccia, E. Abruzzese, M. Tiribelli, M. Bonifacio, A. Tieghi, A. Isidori, B. Martino, N. Sgherza, M. D'Adda, M. Bergamaschi, M. Crugnola, F. Cavazzini, C. Bosi, G. Binotto, G. AuteriR. Latagliata, A. Ibatici, L. Scaffidi, D. Penna, D. Cattaneo, F. Soci, M. Trawinska, D. Russo, A. Cuneo, G. Semenzato, F. Di Raimondo, F. Aversa, R.M. Lemoli, F. Heidel, M.L.B. Reggiani, D. Bartoletti, M. Cavo, L. Catani, N. Vianelli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)248-255
Number of pages8
JournalSeminars in Hematology
Volume55
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • hemoglobin
  • ruxolitinib, adult
  • aged
  • anemia
  • Article
  • drug efficacy
  • drug response
  • female
  • high risk patient
  • human
  • intermediate risk patient
  • International Prognostic Scoring System
  • leukocyte count
  • major clinical study
  • male
  • multicenter study
  • myelofibrosis
  • overall survival
  • phenotype
  • platelet count
  • polycythemia vera
  • priority journal
  • probability
  • prognosis
  • scoring system
  • survival rate
  • thrombocythemia
  • thrombocytopenia
  • validity

Cite this

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎. / Palandri, F.; Palumbo, G.A.; Iurlo, A.; Polverelli, N.; Benevolo, G.; Breccia, M.; Abruzzese, E.; Tiribelli, M.; Bonifacio, M.; Tieghi, A.; Isidori, A.; Martino, B.; Sgherza, N.; D'Adda, M.; Bergamaschi, M.; Crugnola, M.; Cavazzini, F.; Bosi, C.; Binotto, G.; Auteri, G.; Latagliata, R.; Ibatici, A.; Scaffidi, L.; Penna, D.; Cattaneo, D.; Soci, F.; Trawinska, M.; Russo, D.; Cuneo, A.; Semenzato, G.; Di Raimondo, F.; Aversa, F.; Lemoli, R.M.; Heidel, F.; Reggiani, M.L.B.; Bartoletti, D.; Cavo, M.; Catani, L.; Vianelli, N.

In: Seminars in Hematology, Vol. 55, No. 4, 2018, p. 248-255.

Research output: Contribution to journalArticle

Palandri, F, Palumbo, GA, Iurlo, A, Polverelli, N, Benevolo, G, Breccia, M, Abruzzese, E, Tiribelli, M, Bonifacio, M, Tieghi, A, Isidori, A, Martino, B, Sgherza, N, D'Adda, M, Bergamaschi, M, Crugnola, M, Cavazzini, F, Bosi, C, Binotto, G, Auteri, G, Latagliata, R, Ibatici, A, Scaffidi, L, Penna, D, Cattaneo, D, Soci, F, Trawinska, M, Russo, D, Cuneo, A, Semenzato, G, Di Raimondo, F, Aversa, F, Lemoli, RM, Heidel, F, Reggiani, MLB, Bartoletti, D, Cavo, M, Catani, L & Vianelli, N 2018, 'Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎', Seminars in Hematology, vol. 55, no. 4, pp. 248-255. https://doi.org/10.1053/j.seminhematol.2018.05.013
Palandri, F. ; Palumbo, G.A. ; Iurlo, A. ; Polverelli, N. ; Benevolo, G. ; Breccia, M. ; Abruzzese, E. ; Tiribelli, M. ; Bonifacio, M. ; Tieghi, A. ; Isidori, A. ; Martino, B. ; Sgherza, N. ; D'Adda, M. ; Bergamaschi, M. ; Crugnola, M. ; Cavazzini, F. ; Bosi, C. ; Binotto, G. ; Auteri, G. ; Latagliata, R. ; Ibatici, A. ; Scaffidi, L. ; Penna, D. ; Cattaneo, D. ; Soci, F. ; Trawinska, M. ; Russo, D. ; Cuneo, A. ; Semenzato, G. ; Di Raimondo, F. ; Aversa, F. ; Lemoli, R.M. ; Heidel, F. ; Reggiani, M.L.B. ; Bartoletti, D. ; Cavo, M. ; Catani, L. ; Vianelli, N. / Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎. In: Seminars in Hematology. 2018 ; Vol. 55, No. 4. pp. 248-255.
@article{86d70aaf26c64399a181550cf2acca54,
title = "Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎",
keywords = "hemoglobin, ruxolitinib, adult, aged, anemia, Article, drug efficacy, drug response, female, high risk patient, human, intermediate risk patient, International Prognostic Scoring System, leukocyte count, major clinical study, male, multicenter study, myelofibrosis, overall survival, phenotype, platelet count, polycythemia vera, priority journal, probability, prognosis, scoring system, survival rate, thrombocythemia, thrombocytopenia, validity",
author = "F. Palandri and G.A. Palumbo and A. Iurlo and N. Polverelli and G. Benevolo and M. Breccia and E. Abruzzese and M. Tiribelli and M. Bonifacio and A. Tieghi and A. Isidori and B. Martino and N. Sgherza and M. D'Adda and M. Bergamaschi and M. Crugnola and F. Cavazzini and C. Bosi and G. Binotto and G. Auteri and R. Latagliata and A. Ibatici and L. Scaffidi and D. Penna and D. Cattaneo and F. Soci and M. Trawinska and D. Russo and A. Cuneo and G. Semenzato and {Di Raimondo}, F. and F. Aversa and R.M. Lemoli and F. Heidel and M.L.B. Reggiani and D. Bartoletti and M. Cavo and L. Catani and N. Vianelli",
note = "cited By 0",
year = "2018",
doi = "10.1053/j.seminhematol.2018.05.013",
language = "English",
volume = "55",
pages = "248--255",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎

AU - Palandri, F.

AU - Palumbo, G.A.

AU - Iurlo, A.

AU - Polverelli, N.

AU - Benevolo, G.

AU - Breccia, M.

AU - Abruzzese, E.

AU - Tiribelli, M.

AU - Bonifacio, M.

AU - Tieghi, A.

AU - Isidori, A.

AU - Martino, B.

AU - Sgherza, N.

AU - D'Adda, M.

AU - Bergamaschi, M.

AU - Crugnola, M.

AU - Cavazzini, F.

AU - Bosi, C.

AU - Binotto, G.

AU - Auteri, G.

AU - Latagliata, R.

AU - Ibatici, A.

AU - Scaffidi, L.

AU - Penna, D.

AU - Cattaneo, D.

AU - Soci, F.

AU - Trawinska, M.

AU - Russo, D.

AU - Cuneo, A.

AU - Semenzato, G.

AU - Di Raimondo, F.

AU - Aversa, F.

AU - Lemoli, R.M.

AU - Heidel, F.

AU - Reggiani, M.L.B.

AU - Bartoletti, D.

AU - Cavo, M.

AU - Catani, L.

AU - Vianelli, N.

N1 - cited By 0

PY - 2018

Y1 - 2018

KW - hemoglobin

KW - ruxolitinib, adult

KW - aged

KW - anemia

KW - Article

KW - drug efficacy

KW - drug response

KW - female

KW - high risk patient

KW - human

KW - intermediate risk patient

KW - International Prognostic Scoring System

KW - leukocyte count

KW - major clinical study

KW - male

KW - multicenter study

KW - myelofibrosis

KW - overall survival

KW - phenotype

KW - platelet count

KW - polycythemia vera

KW - priority journal

KW - probability

KW - prognosis

KW - scoring system

KW - survival rate

KW - thrombocythemia

KW - thrombocytopenia

KW - validity

U2 - 10.1053/j.seminhematol.2018.05.013

DO - 10.1053/j.seminhematol.2018.05.013

M3 - Article

VL - 55

SP - 248

EP - 255

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4

ER -